# US 2011/0256095 A1 · Tissue Matrix System

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0256095 A1
- Document ID: US20110256095A1
- Status: Published application
- Kind: A1
- Application number: 13/167,537
- Filed: 2011-06-23
- Published: 2011-10-20
- Earliest claimed: 2004-07-12
- Assignees: ISTO Technologies, Inc.
- Inventors: Mitchell S. Seyedin; Gary Gage
- Web page: https://patentgrep.com/patent/US20110256095A1

## CPC

- A61K 31/727: Heparin; Heparan
- A61K 31/728: Hyaluronic acid
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/04: for non-specific disorders of the connective tissue
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61L 2400/06: Flowable or injectable implant compositions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application discloses matrix compositions to support the repair of tissue defects such as an injury to tendon tissue, ligament tissue, vascular tissue, dermal tissue, or muscle tissue. A matrix described herein comprises a polyester polymer entangled with a polysaccharide polymer. Also disclosed are methods of preparing a matrix, and methods of using a matrix in the repair of tissue. In certain configurations, a matrix can comprise a polyester cross-linked with a polysaccharide, which can be an oxidized polysaccharide. In some configurations, a matrix can further comprise one or more additional components, such as a growth factor or an anti-infective agent. In some configurations, a matrix can be a viscous fluid or a paste, while in other configurations a matrix can be comprised by a solid such as a plug, a granule or a membrane.

## Claims

### Claim 1

A matrix composition for supporting repair of a tissue comprising polyester polymers entangled with hyaluronic acid polymers, said composition being formed by the steps of: (i) dissolving polyester polymers in an organic solvent; (ii) blending the polyester polymers with hyaluronic acid polymers contained in an aqueous medium to form an emulsifed mixture; (iii) freezing the emulsified mixture of the two polymers, and (iv) successively removing the organic solvent and water from the frozen mixture; wherein said composition is characterized by (i) retention of pore structure when hydrated and (ii) the ability to support the growth of cells in vivo or ex vivo.

### Claim 2 (depends on 1)

The matrix of claim 1, wherein steps (iii) and (iv) comprise lyophilizing the emulsified mixture.

### Claim 3 (depends on 2)

The matrix of claim 2, comprising particles formed from the lyophilized the emulsified mixture.

### Claim 4 (depends on 3)

The matrix of claim 3, wherein the particles are combined with an aqueous liquid to form a paste or viscous liquid capable of injection at a tissue site.

### Claim 5 (depends on 4)

The matrix of claim 4, wherein the particles are mixed with an aqueous liquid selected from the group consisting of water, physiological saline, blood, serum, plasma, a hyaluronic acid solution and a protein solution.

### Claim 6 (depends on 5)

The matrix of claim 5, wherein the aqueous liquid comprises a hyaluronic acid solution.

### Claim 7 (depends on 5)

The matrix of claim 5, wherein the aqueous liquid comprises a protein solution comprising fibrin.

### Claim 8 (depends on 5)

The matrix of claim 5, further comprising bone marrow aspirate.

### Claim 9 (depends on 4)

The matrix of claim 4, further comprising at least one therapeutic agent.

### Claim 10 (depends on 9)

The matrix of claim 9, wherein the at least one therapeutic agent is selected from the group consisting of an anti-infective agent, an analgesic agent, an anti-inflammatory agent, and an immunosuppressive agent.

### Claim 11 (depends on 1)

The matrix of claim 1, wherein the polyester polymers are selected from the group consisting of polylactic acid, polyglycolic acid, and a co-polymer comprising polylactic acid and polyglycolic acid.

### Claim 12 (depends on 1)

The matrix of claim 1, wherein the polyester polymers comprise a co-polymer comprising polylactic acid and polyglycolic acid.

### Claim 13 (depends on 12)

The matrix of claim 12, wherein the polylactic acid and the polyglycolic acid are in a weight ratio of about 10:1 to about 2:1.

### Claim 14 (depends on 12)

The matrix of claim 12, wherein the weight ratio of polylactic acid to polyglycolic acid is about 3:1 to 5:1.

### Claim 15 (depends on 1)

The matrix of claim 1, wherein the hyaluronic acid polymers are oxidized.

### Claim 16 (depends on 1)

The matrix of claim 1, wherein the hyaluronic acid polymers are covalently crosslinked.

### Claim 17 (depends on 1)

The matrix of claim 1, wherein the polyester and the hyaluronic acid polymers are in a weight ratio of from 99:1 to 1:99.

### Claim 18 (depends on 1)

The matrix of claim 1, wherein the polyester polymers comprise a co-polymer comprising polylactic acid and polyglycolic acid, wherein the weight ratio of polylactic acid to polyglycolic acid in the co-polymer is from about 9:1 to about 1:9.

### Claim 19 (depends on 1)

The matrix of claim 1, further comprising at least one growth factor.

### Claim 20 (depends on 19)

The matrix of claim 19, wherein the at least one growth factor is selected from the group consisting of a TGF-β, a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, and an activin.

### Claim 21 (depends on 20)

The matrix of claim 20, wherein the at least one growth factor is a bone morphogenetic protein.

### Claim 22 (depends on 1)

The matrix of claim 1, further comprising at least one collagen.

### Claim 23

A method of repairing a defect in a bone or cartilage region in a patient comprising:
(a) obtaining a matrix composition comprising polyester polymers entangled with hyaluronic acid polymers by the steps of: (i) dissolving polyester polymers in an organic solvent; (ii) blending the polyester polymers with hyaluronic acid polymers contained in an aqueous medium to form an emulsified mixture; (iii) freezing the emulsified mixture of the two polymers, and (iv) successively removing the organic solvent and water from the frozen mixture; and (b) applying the matrix composition to the bone or cartilage defect.

### Claim 24 (depends on 23)

The method of claim 23, wherein steps (iii) and (iv) comprise lyophilizing the emulsified mixture.

### Claim 25 (depends on 24)

The method of claim 24, further comprising particles formed from the lyophilized emulsified mixture.

### Claim 26 (depends on 25)

The method of claim 25, further comprising combining the particles with an aqueous liquid to form a paste or viscous liquid, and wherein applying the matrix composition to the bone or cartilage defect comprises injecting the paste or viscous liquid into the defect.

### Claim 27 (depends on 26)

The method of claim 26, wherein the aqueous liquid is selected from the group consisting of water, saline, blood, serum, plasma, a hyaluronic acid solution and a protein solution.

### Claim 28 (depends on 26)

The method of claim 26, wherein the aqueous liquid comprises a hyaluronic acid solution.

### Claim 29 (depends on 26)

The method of claim 26, wherein the aqueous liquid comprises a protein solution comprising fibrin.

### Claim 30 (depends on 26)

The method of claim 26, further comprising combining the paste or viscous fluid with bone marrow aspirate.

### Claim 31 (depends on 26)

The method of claim 26, further comprising applying at least one therapeutic agent to the bone or cartilage defect.

### Claim 32 (depends on 31)

The method of claim 31, wherein the at least one therapeutic agent is selected from the group consisting of an anti-infective agent, an analgesic agent, an anti-inflammatory agent, and an immunosuppressive agent.

### Claim 33 (depends on 26)

The method of claim 26, further comprising applying at least one growth factor to the bone or cartilage defect.

### Claim 34 (depends on 133)

The method of claim 133, wherein the at least one growth factor is selected from the group consisting of a TGF-β, a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, and an activin.

### Claim 35 (depends on 33)

The method of claim 33, wherein the at least one growth factor is a bone morphogenetic protein.

### Claim 36 (depends on 26)

The method of claim 26, further comprising applying at least one collagen to the bone or cartilage defect.
